Question 1

Berapa harga saham Biogen hari ini?

Accepted Answer

Harga saat ini dari Biogen adalah 130.54 USD — harga tersebut telah meningkat sebesar 3.96% dalam 24 jam terakhir. Pantau kinerja harga saham Biogen lebih dekat di grafik lanjutan.

Question 2

Apa simbol saham Biogen?

Accepted Answer

Tergantung pada bursa, simbol saham bisa berbeda. Misalnya, di bursa NASDAQ, saham Biogen diperdagangkan dengan simbol BIIB.

Question 3

Apakah harga saham BIIB naik?

Accepted Answer

Saham BIIB telah meningkat sebesar 2.55% dalam seminggu terakhir, telah meningkat sebesar 0.62% dalam sebulan terakhir, dan telah menurun sebesar -43.69% dalam setahun terakhir. Lihat lebih banyak data di grafik BIIB.

Question 4

Apa rekomendasi analis untuk BIIB?

Accepted Answer

Hingga 01 lug 2025, dari 19 rekomendasi analis, mayoritas memberikan rating BIIB sebagai hold.

Question 5

Apa kapitalisasi pasar BIIB?

Accepted Answer

Hingga hari ini, BIIB memiliki kapitalisasi pasar sebesar 18.51B USD. Jelajahi daftar saham kami yang diperingkat berdasarkan kapitalisasi pasar untuk membandingkan BIIB dengan saham lainnya.

Question 6

Apakah BIIB merilis laporan keuangan?

Accepted Answer

Ya, Anda dapat melacak keuangan BIIB dalam laporan tahunan dan kuartalan di Profit.com.

Question 7

Kapan tanggal laporan pendapatan BIIB berikutnya?

Accepted Answer

BIIB akan merilis laporan pendapatan berikutnya pada 30 lug 2025. Pantau acara yang akan datang dengan Kalender Pendapatan kami.

Question 8

Berapa pendapatan BIIB untuk kuartal terakhir?

Accepted Answer

BIIB melaporkan pendapatan sebesar $3.44 per saham untuk kuartal terakhir, lebih tinggi dibandingkan dengan estimasi $3.3639 per saham, yang menghasilkan kejutan 2.26%. Estimasi pendapatan untuk kuartal berikutnya adalah $2.9648 per saham. Lihat lebih banyak rincian tentang pendapatan BIIB di Profit.com.

Question 9

Berapa pendapatan BIIB untuk kuartal terakhir?

Accepted Answer

Pendapatan BIIB untuk kuartal terakhir adalah 2.43B USD, lebih tinggi dibandingkan dengan estimasi 2.28B USD. Estimasi pendapatan untuk kuartal berikutnya adalah 2.32B USD. Lihat lebih banyak statistik di laporan keuangan BIIB di Profit.com.

Question 10

Berapa Laba Bersih BIIB untuk kuartal terakhir?

Accepted Answer

Pendapatan bersih BIIB untuk kuartal terakhir adalah 240.5M USD, sementara kuartal sebelumnya menunjukkan 266.7M USD laba bersih yang mencatatkan perubahan -9.82%. Lihat lebih banyak statistik di laporan keuangan BIIB di Profit.com.

Question 11

¿BIIB paga dividendos?

Accepted Answer

No, BIIB no paga dividendos a sus accionistas. Pero puedes explorar una lista de acciones de alto dividendo en Profit.com.

Question 12

¿Cuántos empleados tiene BIIB?

Accepted Answer

A partir de 01 lug 2025, BIIB emplea aproximadamente a 7605 empleados. Consulta si BIIB está en nuestra lista de empleadores más grandes.

Question 13

¿Qué es el EBITDA de BIIB?

Accepted Answer

El EBITDA, que mide el rendimiento operativo de una empresa, refleja sus mejoras en eficiencia. El EBITDA de BIIB es 3.08B USD, con un margen EBITDA actual de 15.07%. Consulta más estadísticas en los rapporti finanziari de BIIB en Profit.com.

Question 14

¿Cómo comprar acciones de BIIB?

Accepted Answer

Al igual que otras acciones, las acciones de BIIB se cotizan en bolsas de valores como NASDAQ. La forma más fácil de comprarlas es a través de un bróker de bolsa en línea. Simplemente abre una cuenta, sigue los procedimientos del bróker y comienza a operar. Alternativamente, puedes practicar comerciando acciones de Tesla en Profit.com en torneos Playtrade o elegir un bróker recomendado para operar directamente.

Question 15

¿Debería invertir en las acciones de BIIB?

Accepted Answer

Invertir en acciones requiere una investigación exhaustiva, que incluye analizar las finanzas de la empresa, las noticias relacionadas y el análisis técnico. Actualmente, las recomendaciones de los analistas técnicos de Tesla muestran una calificación de hold.

Antes de invertir en BIIB, considera suscribirte a Profit PRO, donde puedes practicar el comercio en torneos Playtrade, acceder a informes diarios de mercado impulsados por IA, copiar listas de seguimiento cuidadosamente seleccionadas y seguir los portafolios de los multimillonarios.

Biogen Inc

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

Sage Therapeutics rejects Biogen bid, starts strategic review

Sage sues Biogen in wake of $469M buyout offer: report

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Drugmaker Biogen boosts profit outlook on ‘momentum’ for new drugs

Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction

Sage Therapeutics’ stock dives as failed trial hits Biogen collaboration

IGM Biosciences up 40% following Biogen HI-Bio buy

Biogen inks $1.8B deal to acquire immune drug developer HI-Bio

Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments

Biogen drops controversial Alzheimer’s drug

China approves Alzheimer's treatment Leqembi by Eisai and Biogen https://t.co/L6fn9ObDxr https://t.co/bM0VWP0qdN

Biogen quarterly results top estimates despite complex launch of new Alzheimer’s treatment

Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake

Reata shareholders clear buyout deal with Biogen

Reata Pharmaceuticals climbs as HSR waiting period for sale to Biogen expired

Biogen in $1.5B unsecured loan facility for Reata acquisition

Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering

Larimar, Design higher as they benefit from Biogen deal for Reata

Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B

Biogen to slash 1,000 jobs as it looks to save $700 million

Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch

Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more

US FDA grants standard approval of Eisai/Biogen Alzheimer's drug https://t.co/dPTZVWV7nY https://t.co/tJhiKLMMhK

Movers & Shakers: Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move

FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment

Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff says https://t.co/B8zM9OuUMN https://t.co/kBnCzNJITx

Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff says https://t.co/rT7SXVtPut https://t.co/xEscFEsucz

Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds https://t.co/PPwucQj4cX https://t.co/jc4T3ZHDl7

Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds https://t.co/FVizSAXwgQ https://t.co/ZsPKuBM8R7

Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds https://t.co/4EKjVSspfk https://t.co/nBrtuI75sw

Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says

Millions of Americans are expected to test for Alzheimer’s disease – some with at-home DNA test kits, others at labs — as new drugs for early Alzheimer’s, from partners Eisai and Biogen and Eli Lilly, usher in sweeping changes in treatment https://t.co/D1Ny08kJSN https://t.co/JgfEBUurn0

US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug https://t.co/sx3nKxLoYv https://t.co/wxL63AqsHx

Pfizer, Biogen among hundreds of US drugmakers calling for abortion pill ruling reversal https://t.co/nKnJKMfnHr https://t.co/yjm0WBw4GW

US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug https://t.co/MysxC06M8V https://t.co/jxvX3Sw1y5

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/eRoU2JxunD https://t.co/VAzT0W4iCb

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/Ym1X51nVBV https://t.co/9NTKMbzI1r

Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/Bysx8mHeA4 https://t.co/bpjbjrlj87

Eisai, Biogen say Alzheimer's drug Lecanemab getting priority review in China https://t.co/8L0q1rOVxR https://t.co/L0KELgN969

Biogen CEO bets on Alzheimer's drug, pipeline to return to growth https://t.co/Fyg7ni9vv2 https://t.co/nPYonFlBKc

Biogen CEO bets on Alzheimer's drug, pipeline to return to growth https://t.co/GORyQxXcGd https://t.co/j4pNpDagY6

Biogen sees modest 2023 revenue from Alzheimer's disease drug https://t.co/XL1BwDKqTw https://t.co/uqdedtLHPw

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen https://t.co/Wh8Tcs5azk https://t.co/5J5pZ9use9

Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen https://t.co/kTrEVHePch https://t.co/8oM6hrjRR5

Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen https://t.co/wRxWzvIfq7 https://t.co/GrwduIAOfK

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen https://t.co/JiSVeEebG6 https://t.co/5R3pEbciD4

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen https://t.co/15Wmhb3k6S https://t.co/Slfhelg0Bd

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead https://t.co/8t1jxrKT4a https://t.co/k2Rqhi2hri

FAQ